Application of rhein or curcumin in preparation of medicines for preventing and/or treating diabetic nephropathy

A technology of diabetic nephropathy and rhein, applied in drug combinations, urinary system diseases, metabolic diseases, etc., can solve the symptoms of metabolic acidosis without improving or protecting kidney function, effectively slowing down the progression of the disease, and aggravating renal failure And other issues

Active Publication Date: 2017-05-31
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The chemical drugs clinically used to treat diabetes do not improve or protect the kidney function except for lowering blood sugar. Some hypoglycemic drugs even cause kidney damage. Drugs, biguanide hypoglycemic drugs can easily induce lactic acidosis and aggravate the symptoms of metabolic acidosis in renal failure; hypoglycemic drugs metabolized by the kidneys can increase the burden on the kidneys and cause severe persistent hypoglycemia
[0004] Therefore, the current clinical treatment methods have great limitations and cannot effectively slow down the progression of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhein or curcumin in preparation of medicines for preventing and/or treating diabetic nephropathy
  • Application of rhein or curcumin in preparation of medicines for preventing and/or treating diabetic nephropathy
  • Application of rhein or curcumin in preparation of medicines for preventing and/or treating diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] cell experiment

[0028] This embodiment mainly evaluates the effect and dose-effect relationship of each component. Using the glomerular mesangial cells (EMCs) high-glucose culture model, the effects of rhein, curcumin and stilbene glycosides on the proliferation of EMCs and the synthesis of type IV collagen and laminin were screened.

[0029] 1. MTT colorimetric method to measure the proliferation of rat glomerular mesangial cells (MCs)

[0030] MCs significantly stimulated mesangial cell proliferation when cultured in high glucose environment for 48h.

[0031] MCs were cultured in DMEM medium (purchased from gibco) containing 10% fetal bovine serum at 37 °C, 5% CO 2 Incubated in an incubator, digested with 0.25% trypsin and passaged 2-3 times a week. MTT method was used to detect the proliferation activity of GMCs, and the logarithmic phase rat GMCs were taken, and each well was 2×10 4 -4×10 4 The cells were seeded on a 96-well plate, and after 12 hours of subco...

Embodiment 2

[0062] rat experiment

[0063] Streptozotocin (STZ)-induced type II diabetes rat model

[0064] SD (Spraque-Dawley) male rats, about 10 weeks old, weighing 252±23g, were randomly divided into normal control group and diabetes model group. After 1 week of adaptive feeding, the rats in the model group were fed with high-sugar and high-fat feed (containing 10.0% lard, 20.0% sucrose, 2.5% cholesterol, 1.0% cholate, and 66.5% conventional feed) for 4 weeks to induce Insulin resistance develops. In the fifth week, after the rats in each experimental group were fasted for 12 hours, 30 mg / kg of Streptozotocin (STZ) was intraperitoneally injected, and the same volume of citrate buffer was injected intraperitoneally in the normal control group. One week after the injection, the rats in each group were fasted for 12 hours, then their tails were docked to collect blood, and the fasting blood glucose (FBG) was measured. FBG>16.7mmol / L was considered successful in modeling. The treatmen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine and a composition. The pharmaceutical composition comprises the following raw materials in parts by mol: 1-5 parts of rhein, 1-5 parts of curcumin and 1-5 parts of stibene glucoside. The invention further discloses an application of the pharmaceutical composition in the preparation of medicines for preventing and / or treating diabetic nephropathy and / or reducing blood glucose.

Description

technical field [0001] The application relates to the application of rhein or curcumin in the preparation of drugs for preventing and / or treating diabetic nephropathy and / or lowering blood sugar, in particular to a pharmaceutical composition and pharmaceutical preparation. Background technique [0002] The increasing incidence of diabetes has become a public health problem, and one of its serious complications is diabetic nephropathy. Diabetic nephropathy is a microvascular complication. In the progressive kidney damage, diffuse and nodular glomerulosclerosis can be seen, as well as clinical manifestations such as edema, proteinuria, and hypertension accompanying these pathological changes, and finally directly lead to Renal Failure. Diabetic patients with type I account for 10%, and type II accounts for 90%. Diabetic nephropathy occurs in about 35% of type I and about 25% of type II. Diabetic nephropathy has become the number one cause of end-stage renal disease (ESRD). ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61K31/12A61P13/12A61P3/10A61K31/7034
CPCA61K31/12A61K31/192A61K31/7034A61K2300/00
Inventor 招明高
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap